Decision Diagnostics logo

Decision Diagnostics(OTC) DECN

Market Cap$400.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2002)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
Decision Diagnostics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-06
Decision Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-09-29
1 month+0%USD 0.002026-09-03
3 month+0%USD 0.002026-07-06
Year to date+0%USD 0.002025-12-31
1 year+0%USD 0.002025-09-30
3 year+0%USD 0.002023-10-05
5 year-99.67%USD 0.002021-10-06
Since inception-100%USD 56.572002-02-07

Decision Diagnostics Financials at a Glance

Market Cap

$400.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.13M

Net Income (TTM)

-$8.78M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-6.68 (Low)

Price

$0.00

Volume

23,300

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Nov 27, 2024

DECN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Decision Diagnostics

Decision Diagnostics Corp. specializes in developing electronic medical record technologies optimized for smartphones, focusing on diagnostic solutions and home-use testing products. Founded in 2000 and based in Westlake Village, California, the company aims to enhance healthcare delivery through innovative mobile-centric e-health products.

Products and Services
  • GenUltimate! glucose test strips for personal use
  • PetSure! glucose test strips for pets
  • MD@Hand, a comprehensive management system for healthcare
Growth Outlook
  • Focus on mobile health solutions aligns with increasing telehealth demand
  • Expansion of product offerings in the diabetes management sector
  • Strategic acquisitions to enhance intellectual property portfolio
Financial Highlights
  • Recent quarterly revenue of 518,511, showing consistent sales
  • Trailing twelve months gross profit margin at 25.18%
  • Current ratio of 0.33 indicates liquidity challenges
Decision Diagnostics Corp. is positioned in the healthcare sector, particularly in the medical and pharmaceutical industry. The company’s innovative approach to electronic medical records and diagnostic solutions caters to a growing market that increasingly values mobile health technologies. The focus on diabetes management products, including glucose monitoring systems, highlights the company's commitment to addressing chronic health issues. Recent financial performance indicates a revenue of 518,511 in the latest quarter, reflecting a steady demand for its products. The gross profit margin of 25.18% suggests that the company maintains a reasonable level of profitability relative to its sales. However, the current ratio of 0.33 raises concerns about short-term liquidity, indicating that the company may face challenges in meeting its short-term obligations. Overall, Decision Diagnostics Corp. presents an intriguing opportunity for investors interested in the intersection of technology and healthcare. The company's ongoing efforts to innovate and expand its product offerings could position it well for future growth in a rapidly evolving market.
AI Generated • Sep 22, 2026

Industry

Health Care Technology

Headquarters

Westlake Village, CA 91361, US

DECN Financials

Key Financial Metrics (TTM)

Gross Margin

25.18%

Operating Margin

-106.68%

Net Income Margin

-1499.05%

Return on Equity

-10388.57%

Return on Capital

-61.94%

Return on Assets

-524.76%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$400.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

380.49M

Volume

23.30K

Avg. Volume

5.21K

Financials (TTM)

Gross Profit

$462.23K

Operating Income

-$1.93M

EBITDA

-$2.10M

Operating Cash Flow

-$1.07M

Capital Expenditure

-$36.88K

Free Cash Flow

-$1.11M

Cash & ST Invst.

$210.85K

Total Debt

$3.24M

Decision Diagnostics Performance Analysis

Decision Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42020-12-310.2%
Q12021-03-313.1%
Q22021-06-302.7%
Q32021-09-30-6.1%
Decision Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42020-12-31-41.3%
Q12021-03-3187.7%
Q22021-06-3070.4%
Q32021-09-30-100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2021YOY CHG

Revenue

$518.51K

-0.4%

Gross Profit

$115.28K

+20.1%

Gross Margin

22.23%

N/A

Market Cap

$400.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$66.67

N/A

Employees

6

N/A

Net Income

-$554.92K

+88.3%

EBITDA

-$490.72K

-74.4%

Quarterly Fundamentals

Name
Q3 2021YOY CHG

Total Cash

$210.85K

-65.7%

Total Debt

$3.24M

-3.9%

Accounts Receivable

$897.67K

-24.8%

Inventory

$165.61K

-12.1%

Long Term Debt

$0.00

N/A

Short Term Debt

$3.35M

-7.0%

Return on Assets

-5.25%

N/A

Return on Invested Capital

-2.90%

N/A

Free Cash Flow

-$62.09K

+89.5%

Operating Cash Flow

-$60.47K

+89.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IBXGiBX Group, Inc.
$0.00+0.00%
ROTHPharmaRoth Labs, Inc.
$0.00+0.00%
PRMDPrimeMD Inc
$0.00+0.00%
ITMCItoco Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$30.65+3.44%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$158.91-3.26%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$32.07+0.75%
IBITiShares Bitcoin Trust
$47.21-2.64%

Questions About DECN

What is the current price of Decision Diagnostics?

Decision Diagnostics is trading at $0.00 per share.

What is the 52-week range for Decision Diagnostics?

Over the past 52 weeks, Decision Diagnostics has traded between $0.00 and $0.00.

How much debt does Decision Diagnostics have?

Decision Diagnostics total debt is unavailable.

How much cash does Decision Diagnostics have on hand?

Decision Diagnostics does not have cash on hand data available.

What is Decision Diagnostics’s dividend yield?

Decision Diagnostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.